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Article Information  ABSTRACT 
Received: 9th May 2017  Schizophrenia is a syndromic condition which is characterized by a set of signs and symptoms 
like delusions. It is severe non-curable illness of the brain. If not controlled and treated properly, 
it can lead to severe consequences. One can control these delusions by means of treatment, by 
using Conventional therapy or Novel therapy. There are various advantages of Novel system 
over Conventional system. This review focuses on understanding Novel system and its 
advantages over Conventional system. 
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INTRODUCTION 
Schizophrenia is a disease characterized by various signs and 
symptoms. It is psychotic illness that is characterized by 
delusions, hallucinations, thought disorders and speech 
impairment. Symptoms include 
 
Positive Symptoms: It includes 
 Delusions: It is an unshakable belief in something untrue. 
They are false beliefs. 
 Hallucination: It refers to sensations which refers to be real 
but in reality they are created my mind 
 Garbled sentences: It refers to a condition where a person 
is unable to say a complete sentence.  
 Irrational conclusions: It refers to a condition where a 
person makes conclusions based on what they perceive. 
 Aggressive behavior: It is due hallucinations. Due to 
irrational conclusions, patients become aggressive in 
nature [1-3]   
Negative Symptoms: It includes 
 Withdrawal from society: Due to delusions and aggressive 
behavior, patients are unable to concentrate and this causes 
neglection from the society and they tends to remain alone. 
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 Lack of response: Because of irrational conclusions and 
inability to respond to the situation, patients suffer from 
lack of response.   
 
Schizophrenic patients suffer from cognitive functioning.  
Because of this, such patients have a high chance of attempting 
suicide. From the literature, it is clear that 10% of 
schizophrenic patients attempt suicide [1-3]. 
 
ETIOLOGY OF SCIZOPHRENIA  
 Environmental and Genetic factors: According to research, 
schizophrenia has some co-relation with environmental 
and genetic factor. 
 High Level of Dopamine: Dopamine is considered to be 
the important neurotransmitter for leading to development 
of Schizophrenia. In schizophrenic patient, there is 
elevation in dopamine level in dopaminergic pathway and 
leading to positive symptoms. Because of this, it is 
considered an important culprit in Schizophrenic patient. 
 High Level of Serotonin: High level of serotonin in 
serotonergic pathway causes Schizophrenia and leading to 
negative symptoms. 
 Low Level of Glutamate: Low level of glutamate in 
glutamatergic pathway causing Schizophrenia and its 
decrease level causes confusion [2][4]. 
 
TREATMENT OF SCHIZOPHRENIA 
For treatment of Schizophrenia, there are two types of drug 
classes available 
 
1) Typical antipshycotic drug class: This is the class which 
is also known as FIRST GENERATION DRUG CLASS. 
It includes drug which were developed in late 1950s. It 
includes drug like Haloperidol, Chlorpromazine[4] 
 
2) Atypical antipshycotic drug class: This is the class which 
is also known as SECOND GENERATION DRUG 
CLASS. It includes drug which were developed in 1990s. 
It includes drug like Clozapine, Risperidone [4][5]. 
 
CONVENTIONAL DRUG DELIVERY SYSTEM 
It involves formulation aspects of drugs, where it uses 
conventional knowledge of formulation to formulate a dosage 
form. It is a classical method. 
 
Advantages of conventional delivery system:  
Following are advantages of Conventional delivery system  
 patient appliance 
 cost effective 
 chemically stable 
 no specific packaging required 
 suitable for all types of patients 
 
Disadvantages of conventional delivery system:  
Following are disadvantages of Conventional delivery system 
 no target specific 
 less bioavailability 
 delayed action  
 not suitable in case of emergency 
 frequency of dosing is more 
 prone to high chance of side effects[6][7][8]. 
 
NOVEL DRUG DELIVERY SYSTEM (NDDS) 
It involves approaches, formulation aspects, use of techniques 
and system for movement of pharmaceutical product in body. It 
is advanced method. 
 
Advantages of novel delivery system:  
Following are advantages of Novel delivery system 
 quick action 
 enhanced bioavailability 
 can be used in emergency conditions 
 has less side effects 
 frequency of dosing can be reduced 
 more patient compliance than Conventional system 
 they are target specific 
 
Disadvantages of novel delivery system:  
There are few disadvantages which are listed below 
 costly 
 specialized packing is needed [1][6][7][8][9]. 
 
TYPES OF NOVEL DELIVERY SYSTEM 
Classification of novel drug delivery system with reference to 
release control is:  
1. Matrix Diffusion Types: In which rate of release is 
controlled by diffusion of dissolved drug in the matrix [10].  
a) Rigid Matrix Diffusion: Here, diffusion occurs through rigid 
material like PVP & fatty acids [10][11].  
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b) Swell-able Matrix Diffusion: Here, diffusion occurs through 
Hydrophilic gums like guar gum, tragacanth, HPMC, CMC, 
Xanthan Gum & Polyacrylamides. These are also called as 
Glassy Hydrogels and popular for sustaining or controlling the 
release of highly water soluble drugs [10][12].  
 
c) Reservoir System: Here, polymer contents a coating. 
Thickness of this coating & hardness of micro‐capsules control 
the release of the drug [10][13]. 
 
2. Dissolution Matrix Type: Here, the drug is uniformly 
dispersed throughout in a rate controlling medium waxes like 
bees wax, carnauba wax, hydrogenated castor oil, which 
control the drug dissolution by controlling the rate of 
dissolution. Example of dissolution matrix type is 
encapsulation. In encapsulation, dissolution of drug is 
controlled by dissolution controlling coating system like use of 
cellulose, Polyethylene. Glycols, polymethylacrylates, and 
waxes. Dissolution rate also depend upon coating material 
stability and thickness of coating film [14].          
 
3. Dissolution & Diffusion Controlled Release System: Here, 
the drug is encapsulated in partially soluble membrane, pores 
are created due to soluble parts of coating film which permits 
entry of aqueous medium into core and drug dissolution starts 
by diffusion of dissolved drug out of system. Mixture of water 
soluble PVP and water insoluble ethyl cellulose is used for this 
purpose [15][16]s. 
 
4. Water penetration/Osmotic Pressure Controlled NDDS: 
Due to difference in osmotic pressure, sustained release of drug 
occurs [17]. 
 
5. Hydrogels: It consists of three dimensional structures of 
hydrophilic polymers having chemical and physical cross links 
provide a network structure to hydrogels. These are insoluble 
due to network structure and provide desirable protection of 
liable drugs, proteins and peptides [17].  
 
WHY NOVEL DRUG DELIVERY SYSTEM SHOULD BE 
FAVOURED? 
There are various advantages of Novel delivery system over 
Conventional delivery system, which can be used in treatment 
of Schizophrenia. Following are the advantages  
1) NDDS like sustained released and target oriented, which can 
be more useful in Schizophrenic patients. Schizophrenic 
patients suffer from delusions. These delusions can occur at 
any time of the day. When such patient is administered with 
sustained release dosage form, it can be helpful in controlling 
delusions [18]  
2) With help of NDDS like polymer coating, frequency of 
dosing can be reduced to once a day, where as in case of 
Conventional drug delivery system dosing frequency is 3-4 
times a day [19][20].   
3) With help of NDDS like Osmotic Pressure Controlled, the 
formulation aspects of drugs are improved and because of 
which compatibility of drug in the body increases [21].  
4) By means of NDDS, target oriented pharmacological effects 
are achieved. This had led to decrease in toxicity profile of 
drugs [22].  
5) By Dissolution Controlled System, bioavailability of drug is 
enhanced [23]. 
6) Novel drug delivery system are more patient compliance 
than Convenient drug delivery system [24].  
7) Novel drug delivery system like LIPOSOME have high level 
of Lipophilicity. This can be used in crossing blood brain 
barrier and this can be very useful in treating Schizophrenic 
patients [25][25]. 
  
CONCLUSION 
In order to treat Schizophrenic patients, Novel drug delivery 
system have many advantages over Conventional drug delivery 
system. From the review it is clear that for the treatment of 
Schizophrenic patient, Novel drug delivery system would be 
the most promising approach than Conventional drug delivery 
system. 
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